Abstract
4-{2-[(2-hydroxybenzyl)amino]ethyl}-2,5-dimethoxybenzonitrile (25CN-NBOH) was first reported as a potent and highly selective serotonin 2A receptor (5-HT2AR) agonist in 2014. The compound has since found extensive use as a pharmacological tool in a variety of in vivo and in vitro studies. In the present study, we present an improved and scalable synthesis of 25CN-NBOH making this compound readily available to the scientific community.
Originalsprog | Engelsk |
---|---|
Tidsskrift | SynOpen |
Vol/bind | 5 |
Udgave nummer | 2 |
Sider (fra-til) | 158-160 |
DOI | |
Status | Udgivet - 2021 |